益气养阴散结方联合基础治疗对晚期肺鳞癌患者的疗效与细胞免疫的影响  

fficacy of Yiqi Yangyin Sanjie Formula Combined with Basic Treatment on Patients with Advanced Lung Squamous Cell Carcinoma and Its Effect on Cellular Immunity

作　　者：刘琳瑞 LIU Linrui(Department of Oncology,Nanyang Central Hospital,Nanyang Henan 422000,China)

机构地区：[1]南阳市中心医院肿瘤内科,河南南阳422000

出　　处：《临床研究》2024年第12期103-106,共4页Clinical Research

摘　　要：目的分析应用益气养阴散结方联合紫杉醇+卡铂+替雷利珠单抗在治疗晚期非小细胞肺癌(NSCLC)患者(鳞癌)的临床效果及对患者细胞免疫水平的影响。方法选择南阳市中心医院肿瘤内科2021年10月至2023年9月收治的120例NSCLC患者作为研究对象,根据患者单纯采用紫杉醇^(+)卡铂^(+)替雷利珠单抗进行基础治疗或是在基础治疗上联合益气养阴散结方治疗,将患者分为常规组(60例)和中药联合组(60例)。比较两组患者不同治疗周期的临床疗效差异,并对比患者治疗前后肿瘤标志物指标和细胞免疫水平相关指标的表达水平差异,统计对比两组患者治疗期间毒副反应和并发症的发生情况差异。结果治疗4周期后,两组患者的客观缓解率(ORR)和疾病控制率(DCR)对比差异无统计学意义(P>0.05)。治疗8周期后,中药联合组患者ORR和DCR均明显高于常规组,差异均有统计学意义(P<0.05)。治疗前,两组患者肿瘤标志物CEA、CYFRA21-1和CA125的水平对比差异无统计学意义(P>0.05)。治疗后,两组患者上述肿瘤标志物水平均较本组治疗前明显降低,差异均有统计学意义(P<0.05);且中药联合组患者CEA、CYFRA21-1和CA125均明显低于常规组,差异均有统计学意义(P<0.05)。治疗前,两组患者细胞免疫水平相关指标CD3^(+)T淋巴细胞、CD4^(+)T淋巴细胞、CD8^(+)T淋巴细胞及NK细胞的水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者的CD3^(+)T淋巴细胞、CD4^(+)T淋巴细胞水平均较本组治疗前明显增加,而CD8^(+)T淋巴细胞较治疗前明显降低,中药联合组患者NK细胞水平较本组治疗前明显增加,差异均有统计学意义(P<0.05);中药联合组患者的CD3^(+)T淋巴细胞、CD4^(+)T淋巴细胞及NK细胞水平明显高于常规组,而CD8^(+)T淋巴细胞明显低于常规组,差异均有统计学意义(P<0.05)。除了脱发外,中药联合组患者治疗期间骨髓抑制、胃肠道反应、肝功能损伤�Objective To analyze the clinical efficacy of using Yiqi Yangyin Sanjie Formula combined with Paclitaxel,Carboplatin,and Tislelizumab in the treatment of patients with advanced non-small cell lung cancer(NSCLC)(squamous cell carcinoma)and its impact on patients'cellular immunity levels.Methods A total of 120 NSCLC patients admitted to the Oncology Department of Nanyang Central Hospital from October 2021 to September 2023 were selected as study subjects.According to whether patients received only the basic treatment of Paclitaxel,Carboplatin,and Tislelizumab or were additionally treated with the Yiqi Yangyin Sanjie Formula,patients were divided into the conventional group(60 cases)and the Chinese medicine combination group(60 cases).The clinical efficacy of different treatment cycles between the two groups was compared,as well as the expression levels of tumor markers and cellular immunity-related indicators before and after treatment.The differences in the incidence of toxic side effects and complications during treatment were statistically compared between the two groups.Results After four cycles of treatment,there was no statistically significant difference in the Overall Response Rate(ORR)and Disease Control Rate(DCR)between the two groups(P>0.05).After eight cycles of treatment,the ORR and DCR in the Chinese medicine combination group were significantly higher than those in the conventional group,with statistically significant differences(P<0.05).Before treatment,there was no statistically significant difference in the levels of tumor markers CEA,CYFRA21-1,and CA125 between the two groups(P>0.05).After treatment,the levels of the above tumor markers in both groups were significantly lower than before treatment,with statistically significant differences(P<0.05);the levels of CEA,CYFRA21-1,and CA125 in the Chinese medicine combination group were significantly lower than those in the conventional group,with statistically significant differences(P<0.05).Before treatment,there was no statistically significant diff

关 键 词：非小细胞肺癌 益气养阴散结方 临床疗效 细胞免疫 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]